Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Geisler, J.
Right arrow Articles by Dowsett, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geisler, J.
Right arrow Articles by Dowsett, M.

Clinical Cancer Research, Vol 4, Issue 9 2089-2093, Copyright © 1998 by American Association for Cancer Research

ARTICLES

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

J Geisler, N King, G Anker, G Ornati, E Di Salle, PE Lonning and M Dowsett
Department of Oncology, Haukeland University Hospital, Bergen, Norway.

The effect of exemestane (6-methylenandrosta-1,4-diene-3,17-dione) 25 mg p.o. once daily on in vivo aromatization was studied in 10 postmenopausal women with advanced breast cancer. Aromatization was determined before treatment and after 6-8 weeks on therapy by administering a bolus injection of [3H]androstenedione (500 microCi) and [14C]estrone (5 microCi) followed by measurement of the isotope ratio of urinary estrogens after high-performance liquid chromatography purification. In addition, plasma endogenous estrogens were measured with highly sensitive radioimmunoassays after separation with high-performance liquid chromatography. Treatment with exemestane suppressed whole body aromatization from a mean pretreatment value of 2.059% to 0.042% (mean suppression of 97.9%). Plasma levels of estrone, estradiol, and estrone sulfate were found to be suppressed by 94.5%, 92.2%, and 93.2%, respectively. This is the first study revealing near total aromatase inhibition in vivo with the use of a steroidal aromatase inhibitor. The observation that exemestane is a highly potent aromatase inhibitor, together with the fact that the drug is administered p.o. and causes limited side effects, suggests that exemestane is a promising new drug for the treatment of hormone sensitive breast cancer.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. Geisler, H. Helle, D. Ekse, N. K. Duong, D. B. Evans, Y. Nordbo, T. Aas, and P. E. Lonning
Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels
Clin. Cancer Res., October 1, 2008; 14(19): 6330 - 6335.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Lester, D. Dodwell, O. P. Purohit, S. A. Gutcher, S. P. Ellis, R. Thorpe, J. M. Horsman, J. E. Brown, R. A. Hannon, and R. E. Coleman
Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 6336 - 6342.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Markopoulos, A. Polychronis, U. Dafni, D. Koukouras, V. Zobolas, E. Tzorakoleftherakis, G. Xepapadakis, and H. Gogas
Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy
Ann. Onc., August 4, 2008; (2008) mdn545v1.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. R. Miller, J. Bartlett, A. M. H. Brodie, R. W. Brueggemeier, E. di Salle, P. E. Lonning, A. Llombart, N. Maass, T. Maudelonde, H. Sasano, et al.
Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?
Oncologist, August 1, 2008; 13(8): 829 - 837.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Chia, W. Gradishar, L. Mauriac, J. Bines, F. Amant, M. Federico, L. Fein, G. Romieu, A. Buzdar, J. F.R. Robertson, et al.
Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results From EFECT
J. Clin. Oncol., April 1, 2008; 26(10): 1664 - 1670.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Y. Dirix, J. Ignacio, S. Nag, P. Bapsy, H. Gomez, D. Raghunadharao, R. Paridaens, S. Jones, S. Falcon, M. Carpentieri, et al.
Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib
J. Clin. Oncol., March 10, 2008; 26(8): 1253 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. U. Lin and E. P. Winer
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
J. Clin. Oncol., February 10, 2008; 26(5): 798 - 805.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. U Buzdar and J. F. Robertson
Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer
Ann. Pharmacother., September 1, 2006; 40(9): 1572 - 1582.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. D. Ryan and P. E. Goss
Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer
Oncologist, July 1, 2006; 11(7): 718 - 731.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Altundag and N. K. Ibrahim
Aromatase inhibitors in breast cancer: an overview.
Oncologist, June 1, 2006; 11(6): 553 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. U. Buzdar and J. Cuzick
Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data
Clin. Cancer Res., February 1, 2006; 12(3): 1037s - 1048s.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
The Breast International Group (BIG) 1-98 Collabor
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
N. Engl. J. Med., December 29, 2005; 353(26): 2747 - 2757.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. E. Lonning, J. Geisler, L. E. Krag, B. Erikstein, Y. Bremnes, A. I. Hagen, E. Schlichting, E. A. Lien, E. S. Ofjord, J. Paolini, et al.
Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
J. Clin. Oncol., August 1, 2005; 23(22): 5126 - 5137.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. W. Brueggemeier, J. C. Hackett, and E. S. Diaz-Cruz
Aromatase Inhibitors in the Treatment of Breast Cancer
Endocr. Rev., May 1, 2005; 26(3): 331 - 345.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Geisler and P. E. Lonning
Aromatase Inhibition: Translation into a Successful Therapeutic Approach
Clin. Cancer Res., April 15, 2005; 11(8): 2809 - 2821.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Strasser-Weippl and P. E. Goss
Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
J. Clin. Oncol., March 10, 2005; 23(8): 1751 - 1759.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. E. Lonning
Exemestane for Breast Cancer Prevention: A Feasible Strategy?
Clin. Cancer Res., January 15, 2005; 11(2): 918s - 924s.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. M. Campos
Aromatase Inhibitors for Breast Cancer in Postmenopausal Women
Oncologist, April 1, 2004; 9(2): 126 - 136.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. C. Coombes, E. Hall, L. J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S. E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, et al.
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
N. Engl. J. Med., March 11, 2004; 350(11): 1081 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. E. Smith and M. Dowsett
Aromatase Inhibitors in Breast Cancer
N. Engl. J. Med., June 12, 2003; 348(24): 2431 - 2442.
[Full Text] [PDF]

Home page
 JCOHome page
E. P. Winer, C. Hudis, H. J. Burstein, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, J. Gralow, L. J. Goldstein, K. I. Pritchard, et al.
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002
J. Clin. Oncol., August 1, 2002; 20(15): 3317 - 3327.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Geisler, B. Haynes, G. Anker, M. Dowsett, and P. E. Lonning
Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study
J. Clin. Oncol., February 1, 2002; 20(3): 751 - 757.
[Abstract] [Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
E. R. Simpson and M. Dowsett
Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy
Recent Prog. Horm. Res., January 1, 2002; 57(1): 317 - 338.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
P. E. Lonning
Aromatase inhibitors and inactivators in breast cancer
BMJ, October 20, 2001; 323(7318): 880 - 881.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Buzdar and A. Howell
Advances in Aromatase Inhibition: Clinical Efficacy and Tolerability in the Treatment of Breast Cancer
Clin. Cancer Res., September 1, 2001; 7(9): 2620 - 2635.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Geisler, S. Detre, H. Berntsen, L. Ottestad, B. Lindtjørn, M. Dowsett, and P. E. Lønning
Influence of Neoadjuvant Anastrozole (Arimidex) on Intratumoral Estrogen Levels and Proliferation Markers in Patients with Locally Advanced Breast Cancer
Clin. Cancer Res., May 1, 2001; 7(5): 1230 - 1236.
[Abstract] [Full Text]

Home page
 JCOHome page
P. E. Goss and K. Strasser
Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer
J. Clin. Oncol., February 1, 2001; 19(3): 881 - 894.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. E. Lonning, E. Bajetta, R. Murray, M. Tubiana-Hulin, P. D. Eisenberg, E. Mickiewicz, L. Celio, P. Pitt, M. Mita, N. K. Aaronson, et al.
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
J. Clin. Oncol., June 11, 2000; 18(11): 2234 - 2244.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.